EMA committee recommends AstraZeneca’s ovarian cancer drug Lynparza
Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumor DNA repair pathway deficiencies to kill cancer cells. The drug is indicated to patients who are in
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.
As previously announced, Islet Sciences and BHV have entered into a merger agreement that will combine the operations and development pipelines of the two companies. Upon closing of
The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers. Epizyme also announced the
Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology. "Immuno-oncology is a significant area of